Trial Profile
A Phase II Trial of Inhibition of CD26 Peptidase Using Sitagliptin to Enhance Engraftment After Umbilical Cord Blood Transplantation for Adults With Hematological Malignancies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Stem cell engraftment
- Focus Therapeutic Use
- 15 Apr 2015 New trial record
- 19 Oct 2013 Status changed from active, no longer recruiting to completed according to results published in the Clinical Pharmacokinetics.